Back to results
US 2023/0295661 A1Published application
Persistent hsv gene delivery system
AssigneeUniversity of Houston System
InventorsShaun ZHANG, Xinping FU
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Houston System
InventorsShaun ZHANG, Xinping FU
Estimating the term…
This invention relates to herpes simplex virus (HSV) based vectors for delivering transgenes (e.g., a therapeutic gene) which are more resistant to neutralization, phagocytosis, and NK cells by immune systems, and methods for their preparation and treatment of disorders and diseases (such as those related to gene expression) with them. In one embodiment, the HSV vectors are prepared by treatment in immune sera that contain a high level of anti-HSV antibodies. The HSV vectors may include an extracellular CD47 domain inserted into the N-terminus of a glycoprotein in order to inhibit phagocyte activity, and the absence of gE for evading NK cells.
A non-replicating herpes simplex virus (HSV) based gene delivery vector, wherein (i) the HSV vector comprises a transgene, and (ii) the HSV vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N-terminus of the glycoprotein.
A composition comprising a non-replicating herpes simplex virus (HSV) based gene delivery vector, wherein (i) the HSV-based vector comprises a transgene, and (ii) the HSV-based vector is prepared by passaging at least twice the HSV-based vector with immune sera having elevated levels of anti-HSV antibodies.
A method of preparing a composition comprising a non-replicating HSV-based vector comprising passaging at least twice an HSV-based vector comprising a transgene with immune sera that has elevated levels of anti-HSV antibodies.
Dependencies are inferred from the claim text.